Phaseline

Companies › Replimune

Replimune: clinical trials, targets and expected readouts

4 active drug programs in 11 registered trials: 6 Phase 2, 4 Phase 1, 1 Phase 3; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vusolimogene Oderparepvec
Genetically modified Herpes Simplex Type 1 Virus (oncolytic immunotherapy)
–Phase 3Advanced Melanoma; AngiosarcomaSep 2030
RP2
Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation
–Phase 2Hepatocellular Carcinoma; Metastatic Uveal Melanoma; Cancer; High-Risk Oral Precancerous DiseaseDec 2027
RP1
Genetically modified herpes simplex virus type 1 (HSV-1) immunotherapy
–Phase 2Cutaneous Squamous Cell Carcinoma; Non-Small Cell Lung Cancer (NSCLC); Merkel Cell Carcinoma; Squamous Cell CarcinomaJun 2028
RP3
Genetically modified HSV-1 oncolytic virus
–Phase 1Advanced Solid TumorNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04050436RP1Phase 2Cutaneous Squamous Cell CarcinomaOncologySep 2025
NCT05858229RP1Phase 1Squamous Cell CarcinomaOncologyDec 2025
NCT04336241RP2Phase 1CancerOncologyOct 2026
NCT04735978RP3Phase 1Advanced Solid TumorOncologyNov 2026
NCT06623110RP2Phase 2High-Risk Oral Precancerous DiseaseOncologyJan 2027
NCT05733598RP2Phase 2Hepatocellular CarcinomaOncologyDec 2027
NCT03767348RP1Phase 2Non-Small Cell Lung Cancer (NSCLC)OncologyJun 2028
NCT04349436RP1Phase 1Merkel Cell CarcinomaOncologyJul 2029
NCT06898970Vusolimogene OderparepvecPhase 2AngiosarcomaOncologyOct 2029
NCT06581406RP2Phase 2Metastatic Uveal MelanomaOncologyJan 2030
NCT06264180Vusolimogene OderparepvecPhase 3Advanced MelanomaOncologySep 2030

From the company's SEC filings

Cash and short-term investments of $308m on 2026-09-30; operating cash outflow about $248m a year; runway about 15 months at that burn, to Dec 2027; 2 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Actinium Pharmaceuticals ALX Oncology Kura Oncology Oncolytics Biotech Cardiff Oncology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.